30% lose response by 12 months, with a further 10% losing response annually thereafter. [5] [6] [7] Accordingly, there is a need to understand whether there are factors that are associated with response and loss of response to improve outcomes.
Immunogenicity is a well-recognized mechanism implicated in ADA failure. 8 Antibodies to ADA have been shown to influence the pharmacokinetics of ADA, leading to increased drug clearance and lower ADA levels. 9 The use of concomitant immunomodulation (CIM) with anti-TNF agents decreases antidrug antibody formation. [10] [11] [12] In the case of infliximab (IFX), combination therapy is superior to monotherapy both for patients with Crohn's disease and those with ulcerative colitis. [11] [12] [13] However, there is less evidence for a similar effect with ADA. A recently published prospective open-label study of 176 treatment-naive patients with moderate-to-severe Crohn's disease randomized to ADA monotherapy compared with combination therapy with azathioprine (AZA) found no difference in rates of clinical remission at week 26. 14 Furthermore, there were no differences in the proportion of patients meeting the primary endpoint when patients were stratified according to week 12 thioguanine nucleotide (TGN) threshold of 250 pmol/8 · 10 8 red blood cell (RBC) (P ¼ 0.13). However, they found significantly higher endoscopic remission at week 26 in the combination group, indicating likely benefit of combination therapy. Further evidence regarding the need for CIM when using ADA is based on subanalysis of randomized controlled trials and retrospective studies. 8, 15 The results of these studies are conflicting, suggesting that further data would be of use. Studies assessing whether the intensity of CIM (in the case of thiopurines measured using 6-thioguanine nucleotide metabolites [TGN] ) is of importance are lacking, an area recently addressed in 2 IFX-treated cohorts. 16, 17 The aim of this study was, therefore, to investigate the influence of CIM on clinical outcomes in a well-characterized and prospectively assessed cohort of Crohn's disease patients treated with ADA. In addition, we aimed to assess whether therapeutic TGN concentrations were associated with improved outcomes compared with subtherapeutic TGNs in patients on thiopurine combination therapy.
METHODS

Study Design
We performed a retrospective single-center cohort study of consecutive patients with moderate-to-severe Crohn's disease, who commenced ADA at Guy's and St. Thomas' Inflammatory Bowel Disease Centre between January 2006 and June 2013.
Study Population
The diagnosis of Crohn's disease was based on standard endoscopic, histological, and radiological criteria. 18 Only patients who commenced ADA at our center were included. Data were collected prospectively from January 2009 through our Virtual Biologic Clinic which has been described previously. 19 Within this setting, patients are reviewed before commencing ADA and subsequently every 3 to 6 months, unless indicated earlier. All other data were retrieved from the electronic patient record.
Thiopurines (AZA, mercaptopurine, and thioguanine) or methotrexate (MTX) was commenced at the treating physician's discretion. AZA and mercaptopurine were initially dosed according to body weight (2-2.5 mg/kg AZA, 1-1.5 mg/kg mercaptopurine) after measurement of thiopurine-S-methyltransferase activity [20] [21] [22] with dose reduction by 50% in thiopurine-S-methyltransferase heterozygotes. 23 We routinely measure thiopurine metabolites in all patients (TGN and methylated metabolites) 24 4 weeks after starting therapy to guide dose adjustment; a TGN of 230 to 450 pmol/8 · 10 8 RBC is considered therapeutic. 25 Patients with subtherapeutic TGNs, evidence of hepatotoxicity or intolerance in conjunction with a metabolite profile consistent with hypermethylation (defined as methylated metabolites to TGN ratio . 11:1), were changed to allopurinol 100 mg coprescription with thiopurine dose reduction to 25% to 33% of the original dose. 26 During maintenance, TGNs are routinely performed in patients every 6 to 12 months. MTX was dosed at 15 to 25 mg weekly orally with folic acid supplementation 27 and thioguanine at 20 to 40 mg daily.
Biologics were started as a step-up therapy in patients who either failed or intolerant of immunomodulators. ADA was initiated as the first-line biologic or after failure of IFX. All patients initiated ADA at standard induction dosing (160/80 mg weeks 0 and 2), followed by maintenance (40 mg every other week). In those with an incomplete response after induction or secondary loss of response, ADA was intensified to 40 mg each week. Dose reduction back to 40 mg every other week was considered after attainment of remission, based on a combination of clinical, biochemical, endoscopic, and radiological parameters.
Assessment of Response-Induction
Response to induction was assessed at 12 weeks by physician global assessment after consideration of clinical activity (Harvey-Bradshaw Index 28 [HBI]), biomarkers (C-reactive protein, [CRP] , fecal calprotectin), and imaging or endoscopy, where available. HBI of ,4, CRP , 5 mg/L, and calprotectin ,50 mg/g were considered as markers of response. Patient response was assessed and documented by at least 2 or more experienced inflammatory bowel disease physicians after considering all available parameters.
Patients maintained on a stable dose of immunomodulator $3 months before ADA induction and who continued for a $6 months after induction were defined as CIM at induction. All other patients were classified as not being on CIM at induction. Patients taking thiopurines were further classified according to TGN levels; . 235 was considered therapeutic.
Assessment of Response-Maintenance
Beginning after the first 12 months of treatment, patients were assessed for long-term clinical response, per 6-monthly semesters. Semesters with $3 months of CIM therapy were considered CIM semesters. Patients on thiopurines were again stratified according to TGNs measured from each semester, where available. Semesters were classified per one of 3 definitions:
Flare semester: active clinical disease resulting in treatment intensification (ADA dose escalation, new corticosteroids, or addition of CIM), hospital admission due to active Crohn's disease, new perianal disease or Crohn's disease-related surgery not leading to ADA withdrawal.
Remission semester: semester without a flare either on every other week or weekly dosing.
Failure semester: Failure, defined as withdrawal of ADA due to primary nonresponse, secondary loss of response despite dose intensification, or due to development of adverse effects or complications.
Factors Associated with Clinical Response
Covariates that were assessed for response to induction, ADA failure, dose intensification, and semester outcomes included sex, disease duration, age at diagnosis, disease location and behavior as per Montreal classification, 29 smoking status, weight, previous anti-TNF exposure, previous surgery, CIM $3 months before starting therapy, CIM status during semester, and CRP and HBI at commencing ADA. Interactions between weight and need for ADA dose intensification were also explored.
Statistical Analysis
Categorical variables are presented as number and percentage, and quantitative data as mean with standard deviation or median with interquartile range, as appropriate. Between-group comparisons were performed using Pearson's Chi-squared, independent sample t test, or Mann-Whitney U test. Multivariate analysis was performed using Cox regression for time to failure and binary logistic regression for factors associated with induction outcome, dose escalation, and semesters of remission. Covariates identified a priori with P , 0.1 on univariate analysis were entered into a multivariate backward stepwise model. Variables with P , 0.05 were retained in the final model and reported as adjusted hazard ratios (HRs) in the Cox regression and odds ratios (ORs) in logistic regression with 95% confidence intervals (CIs). Time to ADA failure was calculated using Kaplan-Meir survival analysis, and comparisons between groups were made using the log-rank test. Two-sided P values ,0.05 were considered significant. Statistical analyses were carried out using SPSS v23.0 (SPSS Inc., Chicago, IL).
Ethical Consideration
According to the guidelines of the U.K. Health Research Authority, as the data collected were done so as part of routine clinical care and were evaluated retrospectively, ethical approval was not required. 30 
RESULTS
Patient Characteristics
One hundred fifty-six patients commenced ADA between January 2006 and June 2013; 123 met inclusion criteria for the induction analysis (Fig. 1) . Patient characteristics are shown in Table 1 . CIM was prescribed for $3 months before starting ADA in 77/123 (63%); thiopurines were used in 67/77, MTX in 6, thioguanine in 3, and mycophenolate mofetil in 1. Fifty-seven percent and 59% of patients had previously been exposed to anti-TNF in the CIM and no-CIM cohorts, respectively. No significant differences in baseline CRP, (P ¼ 0.49), albumin (P ¼ 0.19), or HBI (P ¼ 0.052) were observed between CIM and no-CIM groups. Follow-up was similar in both groups (20 versus 22 months, P ¼ 0.4).
A total of 280 semesters among 91 patients were available for the maintenance analysis; 201 (72%) were classified as CIM semesters (143 with immunomodulators $3 months before starting ADA versus 58 who were not) compared with 79 (28%) ADA monotherapy semesters (20 in patients treated with immunomodulators $3 months before starting ADA versus 59 who were not) (P , 0.001). Thiopurines were used in 84% of semesters, of these TGNs were available in 92%; 135 (88%) were therapeutic and 19 (12%) were subtherapeutic.
Primary Response
Complete response was seen in 92/123 (75%) at week 12; the mean CRP improved from 18.8 to 4.4 mg/L and the HBI from 7.5 to 1.6 (see Table, Supplemental Digital Content 1a, http://links. lww.com/IBD/B547). Among complete responders' clinical remission with HBI #4 was seen among 92% and biochemical remission with CRP normalization (,5 mg/L) in 84%. A total of 76.5% achieved both clinical and biochemical remission (see Table, Supplemental Digital Content 1b, http://links.lww.com/IBD/B547). The rate of primary nonresponse was significantly lower among patients treated with CIM (12% versus 30%, P ¼ 0.02) (Fig. 2 ). In addition, complete response was also higher among those treated with CIM compared with those not treated with CIM (83% versus 61%, P ¼ 0.02).
Most (97%) patients treated with thiopurines had TGNs measured before starting ADA; 16% were subtherapeutic. Response to induction was seen in 48 (87%), 7 (70%), and 28 (61%) of those with therapeutic TGNs, subtherapeutic TGNs, and no-CIM, respectively (P ¼ 0.011) (Fig. 3) . In univariate analysis, CIM use at induction and serum albumin were significantly associated with response at week 12 ( Table 2) . On multivariate analysis, therapeutic TGN levels (OR 4.32, 95% CI, 1.41-13.29, P ¼ 0.01) and albumin level (OR 1.09, 95% CI, 1.01-1.18, P ¼ 0.03) were independent predictors of response to induction (Table 2) .
Semester Analysis
Of 280 semesters, every other week dosing was observed in 200 (72%) and weekly in 80 (29%). A similar proportion of CIM and non-CIM semesters were observed in each dosing regimen (every other week 74 versus weekly 68%, P ¼ 0.31). More CIM semesters were classified as remission compared with non-CIM semesters (81% versus 60%, P , 0.0001, Fig. 3 ). Considering CIM semesters, patients with therapeutic TGNs were more likely to be in remission compared with those with subtherapeutic TGNs (86% versus 58%, P ¼ 0.004) (Fig. 4) . In univariate analysis, ileal location (P ¼ 0.001), extraintestinal manifestations of disease (P ¼ 0.03), and semesters with therapeutic TGNs (P , 0.0001) were associated with remission (Table 3) . These covariates remained significant after multivariate analysis (ileal disease location: OR 0.21, 95% CI, 0.08-0.57, P ¼ 0.002, therapeutic TGN: OR 3.71, 95% CI, 1.87-7.34, P , 0.0001).
Factors Associated with ADA Failure
Thirty-five of 123 (29%) ceased ADA during the study; 5/ 35 withdrew because of sustained clinical remission. A further 2/ 35 prescribed ADA to downstage inflammation preoperatively were not continued postoperatively. Hence, 28 patients were subsequently analyzed with regard to ADA failure. The mean time to failure was 58 months (95% CI, 50.5-66.3). CIM $3 months before ADA was associated with longer time to failure compared with those not treated with CIM (68.5 versus 35.7 months, P ¼ 0.009 log rank ) (Fig. 5) .
On univariate analysis, male sex (P ¼ 0.033) and therapeutic TGN (P ¼ 0.03) were associated with time to failure (Table 4) 
Dose Escalation and Factors Associated with Dose Escalation
ADA was escalated to weekly dosing in 34/123 (28%) patients. The mean time to dose escalation was 12.5 months (SD 8.7). All baseline characteristics were considered for univariate analysis (see Table, 
Adverse Events
Serious adverse events occurred in 5 patients during the study. Two malignancies occurred; metastatic breast cancer after 19 months of combination treatment with thioguanine and ADA and transitional cell carcinoma of the bladder after 27 months of ADA monotherapy. A 25-year-old male treated with thioguanine and ADA developed primary EBV infection and recovered after discontinuing both drugs. Two patients developed intraabdominal sepsis, 4 and 10 months into treatment; one was on ADA monotherapy, and the other on combination therapy with AZA.
DISCUSSION
We have demonstrated that in patients with Crohn's disease starting ADA, combination therapy with an immunomodulator was associated with higher rates of clinical response after induction compared with ADA monotherapy and observed lower rates of subsequent ADA failure. During maintenance, combination therapy was associated with a decrease in the proportion of flare semesters. We assessed the relationship of thiopurines stratified according to TGN levels, not previously reported in the literature, and found that subtherapeutic TGNs at induction and during maintenance therapy were associated with worse clinical outcomes and an increased risk of ADA failure compared with patients with therapeutic TGNs.
The situation regarding combination therapy in patients taking IFX has been studied extensively. In a retrospective analysis of 584 semesters among 121 patients with inflammatory bowel disease, Sokol et al found a significantly decreased incidence of flares (32% versus 19%), perianal complications (12% versus 4%), and mean CRP (11% versus 9%) in those treated with combination therapy compared with IFX monotherapy. 31 Many of the patients in this cohort started IFX on failure of immunomodulator therapy and continued CIM after initiating IFX, suggesting that there is a benefit of combination therapy in all patients starting IFX, not just those naive to immunomodulators. This has also been supported by a recent meta-analyses of patient-level data in the biological registration trials. 32 In addition, combination therapy has been shown to improve rates of deep remission (defined as clinical remission together with normalization of CRP and mucosal healing), compared with IFX monotherapy in patients who were previously naive to both drugs (65% versus 25%, P ¼ 0.037). 17 Although the benefits of combination therapy with IFX seem robust, evidence to support the same benefit with ADA is relatively sparse. The same meta-analysis of randomized controlled trials demonstrating a benefit of combination therapy in induction of clinical remission at 6 months with IFX found no such association for combination therapy with ADA (OR 0.88, 95% CI, 0.58-1.35). 32 A recent prospective study randomizing treatment-naive patients with moderate-to-severe Crohn's disease to either ADA monotherapy or combination therapy with a thiopurine found no difference in clinical remission at week 26 between the 2 treatment arms (72% versus 68%) although an improvement in endoscopic activity at week 26 and higher ADA trough levels were observed in those treated with combination therapy. 14 Conversely, a recent meta-analysis among patients with Crohn's disease found that ADA monotherapy was slightly inferior to combination therapy for induction of remission (OR 0.78, 95% CI, 0.64-0.96, P ¼ 0.02) although no such benefit was seen for maintenance of clinical remission (OR 1.08, 95% CI, 0.79-1.48, P ¼ 0.48) nor was combination therapy superior to monotherapy in terms of need for dose escalation (OR 1.13, 95% CI, 0.69-1.85, P ¼ 0.62). 33 Our study builds on previously published open data. A retrospective study from 2 large centers described 207 patients with Crohn's disease and found that CIM maintained for 3 months or more within 6 months of initiating ADA was associated with a lower risk of ADA failure and fewer flare semesters during maintenance. 15 CIM was not, however, associated with improved rates of response to induction therapy nor was ongoing CIM associated with fewer semesters of flare nor with a lower risk of ADA failure. Semesters in which ADA was dosed weekly, rather than every other week, were classified as flares, even if the patient remained well during the semester, which may have influenced these results. It is recognized that secondary loss of response occurs in a significant proportion of patients during ADA maintenance, and that dose escalation can recapture response in many. 6 It is possible to argue that patients who regain response on dose escalation and remain well on weekly dosing are, therefore, not treatment failures but, rather, represent a subgroup of patients who require higher dosing to achieve therapeutic drug levels to maintain remission. 34 In the current study, therefore, a semester requiring dose escalation was classified as a flare; subsequent semesters were classified according to clinical status and were not automatically recorded as flare semesters based on the need for weekly dosing. Interestingly, dose escalation was not associated with time to failure, supporting our study design.
For the first time, we report the association between adequate dosing of thiopurines (TGN . 235 pmol/8 · 10 8 RBC) and clinical response. We found significantly higher response rates in patients with therapeutic compared with subtherapeutic TGNs at both induction (88% versus 70%) and during maintenance (85% versus 58%). In this regard, data are beginning to emerge demonstrating that the intensity of CIM influences the pharmacokinetics of anti-TNF therapy and subsequent clinical outcomes. A Dutch group found that MTX reduced immunogenicity to IFX in a dose-dependent manner, with the odds of developing antidrug antibodies being 0.36 (95% CI, 0.18-0.74) in the 5 to 10 mg/wk, 0.22 (95% CI, 0.10-0.46) in the 12.5 to 20 mg/wk, and 0.14 (95% CI, 0.07-0.28) in patients on .22.5 mg/wk relative to patients not treated with MTX. 35 In addition, in a post hoc analysis of the SONIC study, patients on combination therapy with AZA with an increase of 7 femtoliters in the mean corpuscular volume (delta MCV), used as a surrogate marker for therapeutic TGN levels, were more likely to achieve mucosal healing (75% versus 47% for delta MCV . 7, P ¼ 0.017) and maintain therapeutic trough IFX levels . 3 mg/mL at week 30 (68% versus 39% for delta MCV . 7, P ¼ 0.003). 36 Similarly, in a crosssectional analysis of 72 patients with inflammatory bowel disease, IFX drug levels were higher among those on combination therapy with a thiopurine compared with IFX monotherapy (13 versus 4.8 mg/mL,), and a TGN cutoff of 125 pmol/8 · 10 8 RBC best predicted a significantly higher IFX trough level. 16 Taken together with the findings that higher anti-TNF drug levels are associated with improved rates of remission, 37, 38 these findings suggest that the dose of thiopurine may be of significant importance. A recent Australia New Zealand Consortium cohort study comparing IFX/ADA with or without IM suggested that corticosteroids used at induction or in the preceding 12 months were associated with 9 to 13 times greater risk of flare semester during maintenance. 39 There was significantly higher use of steroids at induction in the no-CIM arm in the current cohort. However, most of these patients were either intolerant of or failed IM therapy, and steroids were used as a bridge to biological therapy. In addition, there was no difference in steroid use between patients with therapeutic and subtherapeutic TGN levels at induction (21.8% versus 37.5%, P ¼ 0.07).
The utility of measuring TGN in patients taking thiopurines as combination therapy is perhaps even greater when one considers rates of nonadherence and the impact of hypermethylation. Adherence to thiopurines is a well-recognized problem in inflammatory bowel disease. 40 Similarly, underdosing with thiopurines has been reported in 29% when weight-based dosing is used. 24 Thiopurine hypermethylation, whereby shunting occurs away from the therapeutic TGNs toward a methylated metabolite profile, is seen in 15% to 20% and is associated with an inability to achieve therapeutic TGN. 41 Without thiopurine metabolite testing, a large proportion of patients will fail to achieve a therapeutic TGN; the structured approach to optimization of thiopurines in our cohort may explain why a greater benefit of CIM was observed compared with other cohorts.
The development of antibodies against ADA has been implicated as a mechanism leading to secondary loss of response and treatment failure. 42, 43 Combination therapy can improve the pharmacokinetics of IFX by increasing drug levels 44 and by decreasing anti-IFX antibody production (RR: 0.50, 95% CI, 0.42-0.59, P , 0.00001). 44 A recent study demonstrated the beneficial effect of concomitant thiopurine in reducing immunogenicity, regardless of previous clinical response to thiopurines. 45 In a retrospective analysis of 536 samples collected from 148 patients analyzed using a drug-tolerant homogenous mobility shift assay, antibodies to ADA were detected in 20% after a median of 34 weeks. 8 CIM was associated with decreased antibody formation (HR: 0.23, 95% CI, 0.06-0.86), and antibodies were associated with future elevated CRP (P ¼ 0.0013) and discontinuation of ADA due to loss of response (OR 3.04, 95% CI, 1.039-9.093). Such immunogenicity occurs early during ADA therapy. A prospective observational cohort study of 272 patients treated with ADA for rheumatoid arthritis found antibodies to ADA in 28% over a 3-year follow-up; in 67% antibodies occurred within the first 28 weeks of therapy. 46 Similarly, antibodies to IFX have also been found to occur early. In a prospective observational study of 125 patients with inflammatory bowel disease, antidrug antibodies occurred in 46% at a median time of 1.5 months (interquartile range 0.5-5.5); 90% developed within 12 months and antidrug antibody free survival was longer in patients taking combination therapy compared with IFX monotherapy (P ¼ 0.003). 47 These findings suggest that early CIM, perhaps even before starting anti-TNF therapy is important, as has previously been shown in murine models. 48 Thiopurines have a slow onset of action, with a mean time to response of 3.1 months. 21 Therefore, it is possible that some of the beneficial effects of combination therapy may be greater in those patients who are established on therapy before starting ADA.
Given the findings from our study (and some others) that early combination therapy is beneficial, and that immunogenicity occurs largely in the first 12 months of ADA therapy, a key question is whether combination therapy should be continued during maintenance. Such a decision must weigh up the benefits and risks of continued combination therapy against withdrawal to ADA monotherapy. In this regard, we demonstrated higher rates of remission semesters in those treated with CIM versus ADA monotherapy (81% versus 60%) and in those with therapeutic compared with nontherapeutic TGNs (85% versus 58%). Further, CIM use during a semester was an independent predictor of remission (OR 2.92, 95% CI, 1.62-5.25, P , 0.0001). Our results are in agreement with those from the Oxford/Liege cohort, where combination therapy beyond 6 months was associated with fewer semesters with flares (14% versus 36%, P ¼ 0.02, OR ¼ 0.31). 15 Recent studies have called into question the benefit of continued CIM during maintenance therapy, suggesting that a lower dose of thiopurine may be equally efficacious as full weight-based dosing. 49 We were unable to explore this association in the current study as only a small proportion of patients (3/65) were found to have TGNs ,125. The benefits of combination therapy must, of course, be balanced with the risks particularly in light of recent safety signals regarding the use of thiopurines. 50, 51 FIGURE 5. Time to adalimumab failure. Kaplan--Meier analysis illustrating time to ADA failure (months) in patients treated (n ¼ 77) and not treated (n ¼ 46) with CIM for $3 months before commencing ADA (and continued for first 6 months).
We acknowledge several limitations with the study. First, patients were not randomized to combination therapy or ADA monotherapy; hence, despite the groups being similarly matched in terms of phenotype, previous anti-TNF exposure, and disease severity they are not directly comparable. Second, as we did not measure ADA drug levels or antibodies to ADA, we cannot prove that the benefit seen with CIM was due to improvements in ADA pharmacokinetics and reductions in immunogenicity. Third, assessment of response to induction and during maintenance was made using a combination of HBI, CRP, and fecal calprotectin. Fourth, a relatively high number of patients were treated with corticosteroids during induction (53%) which may contribute to the relatively high response rate seen overall (75%). However, there was no difference in corticosteroid use in patients who had therapeutic and subtherapeutic levels of TGN. Finally, a relatively small proportion of patients had subtherapeutic TGNs during induction (15%) and maintenance (12%); hence, the conclusion that response rates are superior with therapeutic compared with subtherapeutic TGNs should be interpreted with caution until it has been confirmed in other cohorts. We acknowledge that this distribution of TGNs limited our ability to apply further relevant statistical methodology such as a quartile or ROC analysis.
CONCLUSION
Combination therapy was found to be superior to ADA monotherapy in this cohort of patients with moderate-to-severe Crohn's disease with improved response at induction, more semesters in remission, and a longer time to ADA failure. Further, adequately dosed thiopurines when used as CIM were associated with improved clinical outcomes. We propose that, after carefully balancing the risk and benefit and noting the association of increased risks of lymphoma, nonmelanoma skin cancer and possibly other malignancies, 50 immunomodulators should be initiated 
